SOC plus trastuzumab and pembrolizumab for cholangiocarcinoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 21 Dec 2023: Trial registered, NCT06178445
  2. 17 Apr 2024: Trial started, NCT06178445

The trials

NCT06178445: Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer

State
Under way
Phase
Phase 2
People
24 planned
Started
17 Apr 2024
Primary completion
Dec 2026
Arms
SOC treatment with gemcitabine/cisplatin in combination with trastuzumab and pembrolizumab
Results
None posted
  1. 21 Dec 2023: Trial registered
  2. 17 Apr 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.